Risk of cerebrovascular disease associated with the use of glucocorticoids in XXXX with incident @entity309 : a population-based study.

@entity1 @entity64 @entity309
OBJECTIVES: To determine the effect of glucocorticoids (GC) on the risk of @entity64 ( @entity64 ) in @entity1 with @entity309 ( @entity309 ). METHODS: A population-based cohort study was carried out using administrative health data on 7051 individuals with @entity309 onset between 1997 and 2001 and no exposure to GC before @entity309 onset. Follow-up was until 2006. GC exposure was defined in four ways: current use (yes/no), current dose (mg/day), cumulative dose (grams) and cumulative duration of use (years). All were used as time-dependent variables updated monthly. @entity64 were ascertained using hospitalisation and vital statistics data. Transient ischaemic attacks were not considered as @entity64 . Cox regression models adjusting for demographics, cardiovascular drug use, propensity scores and @entity309 characteristics were used. RESULTS: The mean age of the cohort was 56 years and 66% were @entity1 . Over 6 years' mean follow-up (43 355 @entity1 -years), 178 incident @entity64 cases were identified. GC current use was not associated with a significant increase in the risk of @entity64 (HR=1.41, 95% CI 0.84 to 2.37). Similarly, the models that accounted for daily dose (HR=1.07, 95% CI 0.94 to 1.21 for each 5 mg increase in the daily dose), cumulative duration of use (HR=1.1, 95% CI 0.94 to 1.32 for each year accumulated in the past) and total cumulative dose (HR=1.04, 95% CI 0.99 to 1.08 per gram accumulated in the past) were also not significantly associated with @entity64 . CONCLUSIONS: This large population-based study indicates that GC use is not associated with an increased risk of @entity64 in cases with @entity309 .
